Lack of Response in Severe Pneumocystis Pneumonia to Combined Caspofungin and Clindamycin Treatment: a Case Report  

作　　者：Yao Zhang Hua Zhang Jun Xu Chan Wu Xiao-jun Ma 

机构地区：[1]Department of Infectious Diseases, , Chinese Academy of Medical Sciences ＆ Peking Union Medical College, Beijing 100730, China [2]Department of Scientific Researches, Chinese Academy of Medical Sciences ＆ Peking Union Medical College, Beijing 100730, China [3]Department of Medicine, Provincial Infectious Disease Hospital of Uygur Autonomous Region, Urumqi 830013, China [4]Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences ＆ Peking Union Medical College, Beijing 100730, China

出　　处：《Chinese Medical Sciences Journal》2011年第4期246-248,共3页中国医学科学杂志（英文版）

摘　　要：PNEUMOCYSTIS pneumonia (PCP) is among the most common opportunistic infections in patients with acquired immune deficiency syndrome (AIDS).Although trimethoprim-sulfamethoxazole (TMP-SMX) is the first line therapy for that condition given its efficacy,approximately one third of patients experienced dose-limiting toxicity.1 For cases of severe to moderate PCP,if TMP-SMX treatment fails or is contraindicated,primaquine combined with clindamycin or intravenous pentamidine is recommended as second line therapy.2 However,both primaquine and pentamidine are associated with severe adverse reactions and often unavailable at hospitals in China.3 As a result,other treatment options have been explored.

关 键 词：pneumocystis pneumonia CASPOFUNGIN acquired immune deficiency syndrome TRIMETHOPRIM-SULFAMETHOXAZOLE 

分 类 号：S859.796[农业科学—临床兽医学] S858.28[农业科学—兽医学]